Beaute Bounty Receives FDA CBER Warning Letter for Unlicensed Stem Cell and Placenta Biologics

Beaute Bounty, a Malaysia-based online retailer, has drawn a formal warning letter from FDA's Center for Biologics Evaluation and Research (CBER) for marketing embryonic stem cell and placenta-derived products into the United States without an approved biologics license application or new drug application, a signal that CBER's surveillance of international e-commerce channels is operationally active, not theoretical.

The letter, dated September 25, 2026 and carrying reference CBER 26-729163, identifies three products sold through beautebountymy.com: Evgenis Totipotent Embryonic Stem Cells, Laennec, and Melsmon Placenta Japan. All three are cited as unapproved new drugs under section 505(a) of the FD&C Act and unlicensed biological products under section 351(a)(1) of the Public Health Service Act. Their introduction into U.S. interstate commerce is prohibited under section 301(d) of the FD&C Act.

CBER's basis for drug classification rests on therapeutic claims published directly on the company's website. The Evgenis product page references Parkinson's disease, Alzheimer's, spinal cord injuries, and cardiovascular conditions. Laennec is marketed with stated effects on liver hardening, anemia, and hypertension. Melsmon carries claims around hematopoietic stimulation and epidermal regeneration. Under 21 U.S.C. § 321(g)(1), those claims are sufficient to establish drug intent regardless of the seller's jurisdiction.

The products also fall within the HCT/P framework under 21 CFR Part 1271, issued under section 361 of the PHS Act. Because they do not satisfy the criteria in 21 CFR 1271.10(a), and no exception under 21 CFR 1271.15 applies, they cannot be regulated solely as 361 HCT/Ps and require a BLA or approved application. No such authorization exists for any of the three products.

For regulatory affairs leads monitoring CBER enforcement trends, the cross-border dimension is the operative detail. The agency reviewed a foreign-hosted commercial website, identified specific product claims, and issued a formal enforcement action to a recipient in Kuala Lumpur via email, without a physical U.S. establishment to inspect. That approach reflects a documented CBER priority around unlicensed cell and tissue products reaching U.S. consumers through digital storefronts, and it extends the practical reach of 21 CFR Part 1271 compliance expectations well beyond domestic manufacturers.

Beaute Bounty has not publicly responded to the warning letter, and the FDA's next enforcement step will depend on whether the company demonstrates corrective action within the agency's stated timeframe.

Source: FDA Center for Biologics Evaluation and Research via FDA Warning Letters RSS Feed, October 27, 2026.